European Equities Traded in the US as American Depositary Edge Higher in Wednesday Trading
Needham Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $38
Positive Outlook on Bicycle Therapeutics Driven by Promising Data and Upcoming Updates
Bicycle Therapeutics Plans To Present Data At SABCS; Abstract Outlines Data Showing Enhanced Anti-Tumor Activity Of Zelenectide Pevedotin Monotherapy In Triple-negative Breast Cancer Patients With NECTIN4 Gene Amplification
Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update
Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference
